Scientific Research
Niklassen, J. et al.
Taxane and platinum combination as a predictor of pathologic complete response in I-SPY2 by gene expression breast cancer signatures
American Society of Clinical Oncology (ASCO), Volume 44, June 2026
(Poster presented at ASCO 2026 - view here)
Hahn, B. et al.
mRNA-based profile to predict platin sensitivity in NSCLC assessed by Nanostring: A translational analysis of the ETOP/EORTC SPLENDOUR trial
American Society of Clinical Oncology (ASCO), Volume 44, June 2026
Finn, S.P. et al.
459P mRNA profile to predict platin sensitivity in NSCLC: A translational analysis of the ETOP/EORTC SPLENDOUR trial
European Lung Cancer Congress (ELCC), Volume 11, April 2026
(Poster presented at ELCC 2026 - view here)
Ejlertsen, B. et al.
583P Validation of a cisplatin response predictor in carboplatin-treated metastatic breast cancer patients
Annals of Oncology, Volume 36, September 2025
(Poster presentned at ESMO 2025 - view here)
Nielsen, D.et al.
Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer
Journal of Clinical Oncology, May 2023
Kappel Buhl, I. et al.
A Drug Response Predictor to Guide Treatment for Breast Cancer
Taylor and Francis, 2019
Kappel Buhl, I. et al.
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
PloS One, 2018; 10.1371
Hugger Jacobsen, E et. al.
Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study
Journal of Clinical Oncology, 2018, e13077
Vangsted, A.J. et al.
Drug response prediction in high-risk multiple myelomas
National Library of Medicine, 2018
Kappel Buhl, I. et. al.
Prospective blinded evaluation predicting efficacy of adjuvant cisplatinum and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer
Abstract no.: e20007, ASCO Annual Meeting, Chicago, 2016
Lassen et. al.
Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumor
Cancer Research 76 (14 supplement), July 2016
